Therapeutic immune modulation using noble gas compositions
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10792305-B2
Publication Date
2020-10-06
Expiration Date
Abstract
Described are compositions of matter and protocols useful for treatment of neurological and other disorders associated with inflammatory activities. In some embodiments the invention provides means of modulating neuroinflammation through administration of noble gas containing compositions. In other aspects, the invention provides means of modulating stem cell compartments to enhance endogenous reparative activities or to synergize with existing treatments.
Core Innovation
The invention relates to noble-gas-containing inhalation compositions for modulating immune activity and neuroinflammation, including compositions comprising xenon diluted in air and/or oxygen. The disclosed approach is directed to treating autism spectrum disorder by administering a noble gas containing composition with oxygen and/or air and a defined proportion of noble gas by volume.
The background and summary identify that neuroinflammation and immune mechanisms are involved in autism spectrum disorder, and that immune activity is modulated by noble gases. The document describes immune-related targets and pathways, including inflammatory cytokines such as IFN-gamma, IL-12, IL-17, and TNF-alpha, and discusses rebalancing of T cells and T regulatory cells (Tregs) and reduction of antibody/autoreactivity.
The document provides evidence that noble gas administration suppresses inflammatory cytokine production, including suppression of TNF-alpha and IL-12 production in immune cells following stimulation conditions described in the partial content. It further describes an ASD clinical trial example comparing xenon/argon/oxygen inhalations versus placebo and reporting outcome measures such as ADOS-G, CGI, ABC, Vineland Adaptive Behavior Scale, MCDI, and CPRS-R:L.
Claims Coverage
The partial content provides one independent claim directed to treating autism spectrum disorder by administering a noble gas containing inhalation composition to an identified patient. The claim includes three inventive aspects as refinements across dependent claims: using xenon and/or a xenon donor, specifying a 25% xenon/75% air by volume composition, and specifying xenon administration volume and frequency.
Noble gas treatment of autism spectrum disorder using defined noble-gas volume proportion
Administering to a patient in need thereof a noble gas containing composition comprising oxygen and/or air and a proportion by volume of 20 to 70% of a noble gas at a sufficient concentration and frequency to effectively treat said autism spectrum disorder.
Xenon and/or xenon donor as the noble gas
The method is performed using xenon and/or a xenon donor as the noble gas.
Specific 25% xenon and 75% air by volume composition
The noble-gas-containing composition is 25% xenon and 75% air by volume.
Xenon administration volume and frequency constraints
Xenon gas is administered at 10 liters of the noble gas composition per administration, with 3 administrations per week.
Overall, the claim coverage centers on a method of treating autism spectrum disorder by identifying a patient and administering an inhalation noble gas composition containing oxygen and/or air with a defined 20-70% by-volume noble gas proportion, with dependent refinements specifying xenon/xenon donor, a 25% xenon/75% air mixture, and administration at 10 liters per administration with 3 administrations per week.
Stated Advantages
Modulates immune activity and neuroinflammation.
Suppresses inflammatory cytokine production, including TNF-alpha and IL-12.
Effectively treats autism spectrum disorder.
Documented Applications
Treatment of autism spectrum disorder using noble-gas-containing inhalation compositions, including xenon/argon/oxygen inhalations versus placebo with clinical outcome measures (ADOS-G, CGI, ABC, Vineland Adaptive Behavior Scale, MCDI, and CPRS-R:L).
Use of xenon-related immune modulation in contexts described as in vitro stimulation, including suppression of cytokine production in monocytes and dendritic cells following conditions including LPS and amyloid beta 1-42.
Interested in licensing this patent?